Verona Pharma PLC Issue of Equity

 
TIDMVRP 
 
Verona Pharma plc 
 
                      ("Verona Pharma" or the "Company") 
 
                              Exercise of Options 
 
Verona Pharma plc (AIM: VRP), the drug development company focused on 
first-in-class medicines to treat respiratory diseases, announces that it has 
issued 2,000,000 new ordinary shares in the capital of the Company (the "New 
Shares") following an exercise of share options by a former employee. 
Application has been made to the London Stock Exchange for the New Shares to be 
admitted to trading on AIM, with dealings expected to commence on 6 January 
2017 ("Admission"). 
 
Following Admission, the Company will have a total of 2,568,053,160 Ordinary 
Shares in issue each carrying one voting right. The Company does not hold any 
Ordinary Shares in Treasury. This figure of 2,568,053,160 Ordinary Shares may 
be used by shareholders as the denominator for the calculations by which they 
will determine if they are required to notify their interest in, or a change to 
their interest in, the share capital of the Company under the FCA's Disclosure 
Guidance and Transparency Rules. 
 
For further information please contact: 
 
 Verona Pharma plc                                           Tel: [phone] 
 
 Jan-Anders Karlsson, Chief Executive Officer 
 
 N+1 Singer (Nominated Adviser and Broker)                   Tel: [phone] 
 
 Aubrey Powell/James White 
 
 FTI Consulting                                              Tel: [phone] 
 
 Simon Conway/Stephanie Cuthbert/Natalie Garland-Collins 
 
 
 
 
END 
 

(END) Dow Jones Newswires

December 29, 2016 11:40 ET (16:40 GMT)